A股異動 | 康躍科技復牌後連續兩日漲停 控股股東轉讓29.9%的股份
格隆匯1月8日丨康躍科技(300391.SZ)復牌後第二日漲停,報8.8元,暫成交305萬元,最新總市值30.8億,現有封單27.4萬餘手。公司6日公告稱,控股股東康躍投資擬以8.8486元/股向盛世豐華轉讓其持有的公司1.047億股無限售條件普通股股份(佔公司股份總數的29.90%)。完成後,盛世豐華將成為公司控股股東。公司股份7日復牌。此外,公司擬以自有資金出資1億元設立全資子公司,經營範圍包括與渦輪增壓器和增壓技術有關產品的研究與開發、技術諮詢、技術服務、轉讓、生產、銷售等業務。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.